Background
Phase 2 RCT. 49 patients with stage IV NSCLC (≤3 metastatic sites) with no progression on ≥4 cycles of first-line systemic therapy (platinum-doublet chemotherapy ± immunotherapy). Response or stable disease required. Randomized after first-line therapy completion. Conducted at MD Anderson Cancer Center and University of Colorado.
Interventions and follow up
Arm A: Local consolidative therapy (LCT: SBRT, surgery, or ablation to all active disease sites) + maintenance or observation (N=25)
Arm B: Maintenance therapy or observation alone (N=24)
Primary endpoint: PFS
mFollow up: Updated median 38.8 month
Arm B: Maintenance therapy or observation alone (N=24)
Primary endpoint: PFS
mFollow up: Updated median 38.8 month
Results
PFS: 14.2 vs 4.4 months, HR 0.35 (95% CI 0.18–0.66), P=.0022
OS: 41.2 vs 17.0 months, HR 0.37 (95% CI 0.18–0.84), P=.017
New distant metastasis: 68% (LCT) vs 79% (maintenance/observation)
Time to new lesion development: Longer in LCT arm
OS: 41.2 vs 17.0 months, HR 0.37 (95% CI 0.18–0.84), P=.017
New distant metastasis: 68% (LCT) vs 79% (maintenance/observation)
Time to new lesion development: Longer in LCT arm
Adverse events
Main adverse events: Grade ≥3 AEs: 29% (LCT) vs 21% (maintenance/observation). Most common grade ≥3 with LCT: esophagitis, fatigue, pain at treated sites. No treatment-related deaths in either arm. Toxicity was manageable and consistent with expected profiles for SBRT and surgery.
Conclusions
Local consolidative therapy to all sites of oligometastatic NSCLC after first-line systemic therapy significantly improved both PFS (HR 0.35) and OS (HR 0.37) compared to maintenance/observation. This provides prospective randomized evidence supporting aggressive local therapy for oligometastatic NSCLC as a distinct, potentially curable (or long-term controllable) entity.
Key Limitations
Key Limitations: Very small N=49 — severely underpowered; 7 crossovers in the control arm complicate OS analysis. Open-label design with heterogeneous LCT modalities (SBRT, surgery, ablation) across different disease sites. Mixed histologies, systemic therapies, and primary characteristics. Phase 2 only — confirmatory phase 3 data needed. Enrolled before modern immunotherapy was standard first-line; results may differ in the immunotherapy era. SABR-COMET (Palma, Lancet 2019) provides additional supportive evidence but also has limitations of small N and heterogeneous primaries.
Clinical Context
The Gomez oligometastatic trial established prospective RCT evidence supporting SBRT/local therapy for oligometastatic NSCLC (≤3 sites), transforming practice at major centers. NCCN now includes oligometastatic NSCLC as a distinct category with consideration for aggressive local therapy. ORIOLE (Phillips JCO 2020) and SABR-COMET extend the evidence base. Key ongoing questions: optimal number of metastatic sites (≤3 vs ≤5), timing with systemic therapy (concurrent vs sequential), and patient selection in the immunotherapy-first era. SBRT to all sites before maintenance immunotherapy is now common practice in oligometastatic NSCLC.
References